NeRRe Therapeutics was launched in December 2012 with the aspiration to further develop a rich portfolio of preclinical and clinical neurokinin (NK) receptor antagonists.Find Out More
We believe that the NK receptor system presents one of the most exciting yet clinically under-exploited neuropeptide target classes, which has huge potential for a broad range of indications to provide truly innovative treatments to meet medical unmet needs.
Our focus is on progressing our lead small molecule NK-1 receptor antagonist orvepitant as a novel and highly effective agent to treat the intense pruritus induced by targeted anti-cancer agents that cause patients significant suffering and a poor quality of life.
In keeping with our ambition for this target class we are keen to explore opportunities to further develop the other high-quality NK receptor antagonists in our pipeline to enable the full therapeutic promise of this neuropeptide receptor system to be realised.
Find Out More
Stevenage, UK, 18th March 2014. NeRRe Therapeutics Ltd, which is focused on the development of neurokinin (NK) receptor antagonists for a range of indications, is pleased to announce the appointment of Ian Nicholson as Chief Business Officer (CBO). Ian brings with him over 25 years’ international experience within the life sciences sector, covering both management…
Start of Phase II study of neurokinin-1 receptor antagonist orvepitant for intense pruritus induced by epidermal growth factor receptor inhibitors
NeRRe Therapeutics Ltd, which is focused on the development of neurokinin (NK) receptor antagonists for a range of indications, is pleased to announce the start of a Phase II study of the novel NK-1 receptor antagonist orvepitant.read more
11.5 million GBP Series A Financing from Novo A/S and Advent Venture Partnersread more